Anzeige
Mehr »
Login
Donnerstag, 08.06.2023 Börsentäglich über 12.000 News von 690 internationalen Medien
Große Kurschance vor Fortsetzung der 10X-Rallye!?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A117WF | ISIN: US78667J1088 | Ticker-Symbol: SG7
Tradegate
07.06.23
13:27 Uhr
50,000 Euro
-3,00
-5,66 %
1-Jahres-Chart
SAGE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
SAGE THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
52,5053,0008:08
52,5053,0008:00

Aktuelle News zur SAGE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.05.Expert Ratings for Sage Therapeutics10
02.05.Sage Therapeutics, Inc. - 10-Q, Quarterly Report4
02.05.Sage Therapeutics, Inc. - 8-K, Current Report2
02.05.Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress261CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights...
► Artikel lesen
01.05.Sage Therapeutics Q1 2023 Earnings Preview3
01.05.Sage Therapeutics' Earnings Outlook4
SAGE THERAPEUTICS Aktie jetzt für 0€ handeln
16.03.Sage Therapeutics, Inc. - 8-K, Current Report3
13.03.Analyst Creates Bullish Pitch For Sage Therapeutics Around Greater Enthusiasm For Its Depression Drug, Zuranolone6
09.03.What 5 Analyst Ratings Have To Say About Sage Therapeutics7
23.02.EMA grants ODD to Sage Therapeutics' SAGE-718 to treat Huntington's disease4
22.02.Sage Therapeutics, Inc.: Sage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington's Disease432Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the European Medicines Agency (EMA) granted Orphan Drug...
► Artikel lesen
16.02.Sage Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
16.02.Sage Therapeutics, Inc. - 10-K, Annual Report1
16.02.Sage Therapeutics, Inc. - 8-K, Current Report-
16.02.Sage Therapeutics mixed Q4 earnings; initiates FY23 outlook2
16.02.Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress203CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights...
► Artikel lesen
06.02.Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its 'Incrementally Positive'8
06.02.Sage Therapeutics: FDA To Review NDA For Zuranolone471WESTON (dpa-AFX) - Sage Therapeutics, Inc. (SAGE) and Biogen Inc. (BIIB) announced the FDA has accepted the filing of a New Drug Application for zuranolone in the treatment of major depressive...
► Artikel lesen
06.02.Sage Therapeutics, Inc. - 8-K, Current Report2
06.02.Biogen Inc.: Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression488Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to treat major depressive disorder (MDD) and postpartum depression (PPD)Depression is a public health issue...
► Artikel lesen
Seite:  Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1